Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotechs Complain About International Post-Approval Change Complexity

This article was originally published in The Gold Sheet

Executive Summary

Biopharmaceutical manufacturers say that disparate post-approval requirements and review times are making it increasingly difficult to make necessary changes to their products and that the problem is getting worse. One vaccine manufacturer called the current situation “unsustainable” and others say that it is wreaking havoc on their efforts to manage products when changes have been approved in some markets but not others.

Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS000826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel